“This is to inform you that the Shilpa Medicare Limited’s 100% subsidiary, Shilpa Pharma Lifesciences Limited received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Octreotide,” the company said in a stock exchange filing.
Octreotide, a synthetic peptide produced through solid-phase synthesis, is used in the treatment of conditions such as acromegaly, severe diarrhoea and flushing episodes related to metastatic carcinoid tumours, and profuse watery diarrhoea linked to vasoactive intestinal peptide (VIP) secreting tumours.
Also Read: Supreme Court declines relief to Zydus Lifesciences in breast cancer drug case
“Octreotide is the second peptide molecule in Shilpa’s peptide portfolio. The CEP showcases our expertise and commitment to quality-oriented development and commercial production, which meets the expectations of global quality standards,” Shilpa Medicare said.
This marks the second peptide molecule in Shilpa Pharma Lifesciences’ peptide portfolio, further showcasing the company’s capabilities in quality-driven development and manufacturing.
Shares of Shilpa Medicare Ltd ended at ₹861, down by ₹11.90, or 1.36%, on the BSE.
Also Read: Glenmark Pharma Q2 Results | Drug firm returns to profit, revenue up 7%
(Edited by : Shoma Bhattacharjee)
